Overview

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Diphosphonates